Guildford, UK, 21 May 2008: ReNeuron Group plc (LSE: RENE.L) today announced that it has received a notification of grant from the US Patent and Trademark Office concerning a key patent covering the culturing and isolation of islet progenitor cells for use in its ReN002 programme focused on a cell therapy treatment for Type 1 diabetes.
The patent, "CD56 Positive Human Adult Pancreatic Endocrine Progenitor Cells" (No. 7,371,576), contains broad claims directed to methods of culturing and identifying living islet progenitor cells by way of expression of the CD56 cell surface marker. The cells produced by this invention can be further proliferated in culture to increase cell number and then allowed to form islet cell clusters suitable for subsequent transplantation. In its ReN002 programme, ReNeuron is currently researching a potential islet cell therapy for Type 1 diabetes patients, utilising expanded islet cells which are then enclosed in clinically-tested, immunoprotective capsules prior to transplantation.
ReNeuron has broad patent coverage across all of its stem cell technologies and products, having written or exclusively licensed over 55 issued patents and over 70 further patent applications. Of these, over 30 patents have issued in the key European and US territories.
May 21, 2008
From the News Wire: U.S. Patent on Islet Progenitor
From their web site: